Summary
Nowadays the role of genetic findings in determining the diagnosis, therapy and prognosis of acute myeloid leukemia (AML) has become more valuable. To improve and validate the detection of clonal chromosomal aberrations in leukemia, we designed a combined application of karyotyping with multiplex reverse transcription-polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH), and addressed the expression and distribution of fusion genes among the subtypes of Chinese adult patients with de novo AML. Multiplex RT-PCR assays were performed on 477 samples from newly diagnosed AML patients, and cytogenetic data were obtained from 373 of them by R or G banding techniques and those in some cases were confirmed by FISH. The PCR products in some suspected cases were tested by two-directional sequencing. The results showed that except unqualified samples, fusion genes were detected by multiplex RT-PCR in 211 of 474 patients (44.51%), including AML1-ETO, CBFβ-MYH11, PML-RARα, PLZF-RARα, NPM-RARα, MLL rearrangements, BCR-ABL, DEK-CAN, SET-CAN, TEL-PDGFR, TLS-ERG, AML1-MDS1 (EVI-1). In 373 patients, who took both multiplex RT-PCR and karyotype analysis, the detection rate of chromosomal aberrations by using multiplex RT-PCR and karyotyping was 160/373 (42.89%) and 179/373 (47.98%) respectively, and the combination could optimize the detection rate of clonal genetic abnormalities to 216/373 (57.90%). The PCR results from 11 cases “normal” in karyotyping but abnormal in RT-PCR for MLL rearrangements were confirmed by two-directional sequencing. It is concluded that karyotype studies remain the cornerstone for genetic testing; conventional cytogenetics and molecular-based methods are complementary tests for the detection of clonal genetic aberrations in AML, especially for the cryptic or submicroscopic aberrations. Once a genetic marker has been identified by combined analysis, it could be used to monitor residual disease during/after chemotherapy, by quantitative RT-PCR and/or FISH.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med, 1999,341(14):1051–1062
Lowenberg B. Diagnosis and prognosis in acute myeloid leukemia-the art of distinction. N Engl J Med, 2008,358(18):1960–1962
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002,100(7):2292–2302
Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 2002,100(13):4325–4336
Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood, 1998,92(7):2322–2333
Salto-Tellez M, Shelat SG, Benoit B, et al. Multiplex RT-PCR for the detection of leukemia-associated translocations: validation and application to routine molecular diagnostic practice. J Mol Diagn, 2003,5(4):231–236
Werner M, Wilkens L, Aubele M, et al. Interphase cytogenetics in pathology: principles, methods, and applications of fluorescence in situ hybridization (FISH). Histochem Cell Biol, 1997,108(4–5):381–390
Rowley JD. Chromosomal translocations: revisited yet again. Blood, 2008,112(6):2183–2189
Pallisgaard N, Hokland P, Riishoj DC, et al. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood, 1998,92(2): 574–588
Strehl S, Konig M, Mann G, et al. Multiplex reverse transcriptase-polymerase chain reaction screening in childhood acute myeloblastic leukemia. Blood, 2001,97(3):805–808
Huang M, Li C, Liang H, et al. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 chromosomal translocation in hematologic malignancies. J Huazhong Univ Sci Technol Med Sci, 2006,26(6):661–663
Wu J, Huang L, Huang M, et al. Dominant contribution of malignant endothelial cells to endotheliopoiesis in chronic myeloid leukemia. Exp Hematol, 2009,37(1): 87–91
Look AT. Oncogenic transcription factors in the human acute leukemias. Science, 1997,278(5340):1059–1064
Ni H, Nitta M, Komatsu H, et al. Detection of bcr/abl fusion transcripts by semiquantitative multiplex RT-PCR combined with a colormetric assay in Ph positive leukemia. Cancer Lett, 1998,124(2):173–180
Gogineni SK, Shah HO, Chester M, et al. Variant complex translocations involving chromosomes 1, 9, 9, 15 and 17 in acute promyelocytic leukemia without RAR alpha/PML gene fusion rearrangement. Leukemia, 1997,11(4):514–518
Eclache V, Viguie F, Frocrain C, et al. A new variant t(6;15;17)(q25;q22;q21) in acute promyelocytic leukemia: fluorescence in situ hybridization confirmation. Cancer Genet Cytogenet, 2005,159(1):69–73
Wan TS, Chim CS, So CK, et al. Complex variant 15;17 translocations in acute promyelocytic leukemia. A case report and review of three-way translocations. Cancer Genet Cytogenet, 1999,111(2):139–143
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors contributed equally to this work.
Rights and permissions
About this article
Cite this article
Geng, Z., Zhang, H., Wang, D. et al. Combination of cytogenetic analysis and molecular screening in patients with de novo acute myeloid leukemia. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 32, 501–510 (2012). https://doi.org/10.1007/s11596-012-0087-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-012-0087-6